Seize the opportunity to show off your skills and abilities as an agency in the Communications Team of the Year competition.
News
Parexel to go private in $5bn deal
Parexel International is being snapped up by private equity group Pamplona Capital Management in a deal valued at around $5 billion, including debt, marking further consolidation of the contract research sector.
Novartis’ eye drug on par with Eylea but with fewer injections
Novartis’ eye drug brolucizumab has been proven in trials to be non-inferior to Regeneron/Bayer’s Elyea in treating vision loss in patients with neovascular age-related macular degeneration (nAMD), but with fewer injections than its rival.
Global drug sales forecast to take a downturn
For the first time in 10 years global sales of pharmaceuticals are forecast by Evaluate to take a downturn because of growing pricing pressures.
Novo gets US backing for Victoza cardiovascular data
US regulatory advisors are backing the claim that Novo Nordisk’s Victoza reduces cardiovascular risk in patients with diabetes.
Scientists discover new type of immune cell
Scientists from the UK and US say they have identified a new type of immune cell that could be able to predict which lung cancer patients will benefit most from treatment with an immunotherapy.
Inequalities in Northern Ireland putting child health at risk
The growing divide between rich and poor is risking the health of children in Northern Ireland, warns the Royal College of Paediatrics and Child Health (RCPCH).
Antidepressant use in under 18s jumps 12 percent in England
The number of children and adolescents taking medicines to combat depression and anxiety has jumped 12 percent in a 12-month period, an investigation by The Guardian has revealed.
Current biopharma R&D costs ‘unsustainable’, warns report
Improving return on investment in R&D is “imperative” to the future success of global pharma and biotech companies, warns a new report by Ernst & Young.
GSK’s Benlysta shows sustained disease control in study
Adding GSK’s Benlysta to standard of care in patients with lupus prolonged control of disease activity, according to newly-released findings of a 10-year continuation study.
Novartis’ MabThera biosimilar wins EU nod
Novartis is poised to turn up the pressure on sales of Roche’s monoclonal antibody MabThera/Rituxan after EU regulators approved its cheaper biosimilar version of the mega blockbuster for use across blood malignancies and immunological diseases.
NHS future ‘uncertain’ for Adcetris in ALCL
Cost regulators for NHS treatments in England and Wales say they are currently minded not to recommend Takeda’s Adcetris on the NHS for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL), a cancer of the lymphatic system.
Researchers develop new test to target prostate cancer treatment
UK-based scientists have developed a new three-in-one blood test able to identify the patients with advanced prostate cancer most likely to benefit from PARP inhibitors, with the potential to ‘transform’ treatment of the disease.
Major u-turn sees Roche’s Kadcyla backed for NHS use
In a major turnaround Roche’s Kadcyla will now become routinely available on the NHS to some patients with breast cancer after a confidential deal was reached between the drug giant and NHS England.
Cytox raises £2.6m to help launch Alzheimer’s test
UK precision medicine group Cytox has raised £2.6 million to fund the commercial launch and international roll out of its comprehensive testing service for Alzheimer’s disease.
